POM-VPS Prescription Required

Bravoxin Suspension for Injection for Cattle and Sheep

Active ingredients: Clostridium chauvoei, Clostridium haemolyticum, Clostridium novyi, Clostridium perfringens, Clostridium septicum, Clostridium sordellii, Clostridium tetani

Form

Injection

Species

Cattle Sheep

Manufacturer

Intervet International B.V.

VMD MA No.

06376/5030

What it's used for

For the active immunisation of sheep and cattle against disease associated with infections caused by Clostridium perfringens type A, C. perfringens type B,...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Clostridium chauvoei + Clost...

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Bravoxin Suspension for Injection for Cattle and Sheep — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 26 Mar 2026.

For the active immunisation of sheep and cattle against disease associated with
infections caused by Clostridium perfringens type A, C. perfringens type B,
perfringens type C, C. perfringens type D, Clostridium chauvoei,
type B, Clostridium septicum, Clostridium sordelliiClostridium haemolyticum and
against tetanus caused by Clostridium tetani.
For the passive immunisation of lambs and calves against infections caused by the
above mentioned clostridial species (except C. haemolyticum in sheep).
Onset of immunity:
Sheep and Cattle: 2 weeks after the basic vaccination course (as demonstrated by
serology only).
Duration of active immunity:
As demonstrated by serology only:
Sheep: 1 year against C. perfringens C. novyi type B, C.
sordellii, C. tetani;
< 6 months against ,
Cattle:1 year against C. tetani and C. perfringens
< 1 year against type A, B and C;
< 6 months against type B,, C. haemolyticum,
C. chauvoei.
An anamnestic humoral immune response (immunological memory) to all
components was demonstrated 1 year following the basic course of vaccination.
Duration of passive immunity:
As demonstrated by serology only:
Lambs: At least 2 weeks for C. septicum C. chauvoei;
At least 8 weeks for C. perfringens type B and type C;
At least 12 weeks for C. perfringens type A, C. perfringens type D, C. novyi
type B, and C. sordellii
No passive immunity was observed for C. haemolyticum.
Calves: At least 2 weeks for and;
At least 8 weeks for and C. chauvoei
At least 12 weeks for C. type A, C. perfringens type B, C.
perfringens type C, C. perfringens type D, C. novyi type B, and C. tetani.

Do not use in sick or immunodeficient animals.

Cattle and sheep:
Very common
(>1 animal / 10 animals treated):
Injection site swelling
.Common
(1 to 10 animals / 100 animals treated):
Injection site abscess, injection site
skin discolouration
.
Hyperthermia
.
Uncommon
(1 to 10 animals / 1,000 animals
treated):
Injection site pain
.Very rare
(<1 animal / 10,000 animals treated,
including isolated reports):
Anaphylactic type reaction
.
Up to a mean value of 6 cm in sheep and 15 cm diameter in cattle; sometimes
reactions of up to 25 cm diameter may be seen in cattle. Most local reactions resolve
within 3-6 weeks in sheep and in less than 10 weeks in cattle. In a minority of
animals they may persist longer.
Returns to normal as the local reaction resolves.
Mild.
For 1-2 days post first vaccination.
In such cases appropriate treatment such as adrenaline should be administered
without delay.

Revised: February 2025
AN: 03579/2024
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian,
to either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.

Vaccinate healthy animals only.
The effectiveness of the vaccine in providing passive immunity to young lambs and
calves depends on these animals ingesting adequate amounts of colostrum on the
first day of life.

Revised: February 2025
AN: 03579/2024
Clinical trials have demonstrated that the presence of maternal derived antibodies
(MDA), particularly against C. tetani, C. novyi type B, C. perfringens type A (calves
only), C. chauvoei (lambs only) and C. perfringens type D may reduce the antibody
response to vaccination in young lambs and calves. Therefore, to ensure an optimal
response in young animals with high levels of MDA, the basic vaccination should be
delayed until the levels wane (which is after about 8-12 weeks of age, see section
4.2).

Special precautions for use in animals
It is good practice to observe animals regularly for adverse reactions at the injection
site following vaccination. It is recommended to seek medical advice from a
veterinarian in case of a severe injection site reaction.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
In case of accidental self-injection, seek medical advice immediately and show the
package leaflet or the label to the physician.
Special precautions for the protection of the environment
Not applicable.
Other precautions
Not applicable.

No information is available on the safety and efficacy of this vaccine when used with
any other veterinary medicinal product. A decision to use this vaccine before or after
any other veterinary medicinal product therefore needs to be made on a case by
case basis.

Store and transport refrigerated (2 °C – 8 °C). Do not freeze.
Protect from light.

Revised: February 2025
AN: 03579/2024

C. chauvoei whole culture, inactivated 90% protection**
C. novyi toxoid 3.8 IU*
C. septicum toxoid 3.3 IU*
C. tetani toxoid 4.5 IU*
C. sordellii toxoid 4.4 U
C. haemolyticum toxoid 25.0 U
#
* ELISA According to Ph.Eur.
In house ELISA
** Guinea pig challenge test according to Ph.Eur.
# In vitro toxin neutralisation test based on haemolysis of sheep erythrocytes.
Adjuvant:
Aluminium
3.026 – 4.094 mg
from aluminium potassium sulphate (alum)
Excipients:
Thiomersal 0.05 – 0.18 mg
For the full list of excipients, see section

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.